Itolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD6 |
| Clinical data | |
| Trade names | Alzumab |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
1116433-11-4  |
| ChemSpider | none |
| UNII |
XQQ2RHV14N  |
| (what is this?) (verify) | |
Itolizumab (INN, trade name Alzumab) is a ‘first in class’ humanized IgG1 monoclonal antibody developed by Biocon.[1] It selectively targets CD6, a pan T cell marker involved in co-stimulation, adhesion and maturation of T cells. Itolizumab, by binding to CD6, down regulates T cell activation, causes reduction in synthesis of pro-inflammatory cytokines and possibly plays an important role by reducing T cell infiltration at sites of inflammation.[2] A double blind, placebo controlled, phase III treat –Plaq study of itolizumab successfully met the pre-specified primary end-point of significant improvement in PASI-75 (Psoriasis Area and Severity Index) score after 12 weeks of treatment in patients with moderate to severe psoriasis compared to placebo.[3] Biocon received marketing authorization for the drug from the Drugs Controller General of India (DCGI) in January 2013 and marketing within India commenced in August 2013.[1][4]
References
- 1 2 Jayaramun, Killugudi (December 2013). "Biocon's first-in-class anti-CD6 mAb reaches the market". Nat. Biotechnol. 31 (12). United Kingdom. pp. 1062–3.
- ↑ http://www.biocon.com/docs/PR_080113.pdf?subLink=news
- ↑ http://www.thehindubusinessline.com/companies/article2789996.ece
- ↑ "Biocon's psoriasis drug, Itolizumab receives DCGI marketing authorization". Pharmabiz.com. India: Saffron Media. January 8, 2013.